[Anti-Cancer Drugs for Thyroid Cancer]
1Dept. of Head and Neck Medical Oncology, National Cancer Center Hospital East.
Abstract:
For patients with differentiated thyroid cancer that is refractory to radioiodine therapy, a long-term response with conventional cytostatic drugs is uncommon, and treatment options have historically been limited. Outcomes for these patients have accordingly been limited. Development of molecular-targeted drugs for thyroid cancer has recently progressed, and several drugs have demonstrated significantly improved progression-free survival over placebo in randomized phase III trials. Nothing will bring us greater pleasure than meeting this hitherto unmet need for thyroid cancer. However, the majority of recurrent thyroid cancer patients have slow growing and asymptomatic disease, and these molecular-targeted drugs are not definitely indicated for all cases. Furthermore, toxicity is considerable and the expected treatment duration is more than one year. Without appropriate management of toxicity and patient education, these drugs will worsen quality of life.
Insights
For differentiated thyroid cancer refractory to radioiodine therapy, new molecular-targeted drugs show promise in improving progression-free survival. However, careful toxicity management and patient selection are crucial due to potential quality of life impacts.
Area of Science:
- Oncology
- Pharmacology
Context:
- Differentiated thyroid cancer (DTC) refractory to radioiodine therapy presents limited treatment options and poor outcomes.
- Conventional cytostatic drugs offer uncommon long-term responses in this patient population.
Purpose:
- To review the recent advancements in molecular-targeted drugs for DTC.
- To discuss the efficacy and challenges associated with these novel therapies.
Summary:
- Molecular-targeted drugs have demonstrated significantly improved progression-free survival over placebo in phase III trials for radioiodine-refractory DTC.
- Despite promising efficacy, the majority of recurrent DTC cases are slow-growing and asymptomatic, questioning universal indication for these targeted agents.
- Significant toxicity and long treatment durations (over one year) necessitate careful management and patient education.
Impact:
- These targeted therapies represent a significant advancement in addressing an unmet need in DTC treatment.
- Appropriate toxicity management and patient education are essential to maintain quality of life during treatment.
- Further research is needed to optimize patient selection and treatment protocols for molecular-targeted therapies in DTC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
01:15Drugs that Stabilize Microtubules
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...